Lamivudine 150 mg + Zidovudine 300 mg + Nevirapine 200 mg
This triple-drug antiretroviral formulation combines two nucleoside reverse transcriptase inhibitors with a non-nucleoside reverse transcriptase inhibitor, forming a well-established regimen for the management of HIV-1 infection under nationally and internationally recommended treatment protocols.
Product Details
Therapeutic Class
Nucleoside Reverse Transcriptase Inhibitors (Lamivudine + Zidovudine)
Non-Nucleoside Reverse Transcriptase Inhibitor (Nevirapine)
Indication
Treatment of HIV-1 infection in adults and adolescents as part of combination antiretroviral therapy (ART), in accordance with WHO and NACO recommendations.
Dosage & Administration
To be administered as per recommended dosing schedules or as prescribed by a healthcare professional.
To be used strictly as part of a combination ART regimen.
Storage
Store below 30°C in a dry place, protected from light and moisture.
Disclaimer
Prescription medicine. To be used only under medical supervision and in line with WHO and NACO treatment guidelines.
Pack Size
60 Tablets
Lamivudine 150 mg + Zidovudine 300 mg + Nevirapine 200 mg
This triple-drug antiretroviral formulation combines two nucleoside reverse transcriptase inhibitors with a non-nucleoside reverse transcriptase inhibitor, forming a well-established regimen for the management of HIV-1 infection under nationally and internationally recommended treatment protocols.
Product Details
Therapeutic Class
Nucleoside Reverse Transcriptase Inhibitors (Lamivudine + Zidovudine)
Non-Nucleoside Reverse Transcriptase Inhibitor (Nevirapine)
Indication
Treatment of HIV-1 infection in adults and adolescents as part of combination antiretroviral therapy (ART), in accordance with WHO and NACO recommendations.
Dosage & Administration
To be administered as per recommended dosing schedules or as prescribed by a healthcare professional.
To be used strictly as part of a combination ART regimen.
Storage
Store below 30°C in a dry place, protected from light and moisture.
Disclaimer
Prescription medicine. To be used only under medical supervision and in line with WHO and NACO treatment guidelines.
Pack Size
60 Tablets
Lamivudine 150 mg + Zidovudine 300 mg + Nevirapine 200 mg
This triple-drug antiretroviral formulation combines two nucleoside reverse transcriptase inhibitors with a non-nucleoside reverse transcriptase inhibitor, forming a well-established regimen for the management of HIV-1 infection under nationally and internationally recommended treatment protocols.
Product Details
Therapeutic Class
Nucleoside Reverse Transcriptase Inhibitors (Lamivudine + Zidovudine)
Non-Nucleoside Reverse Transcriptase Inhibitor (Nevirapine)
Indication
Treatment of HIV-1 infection in adults and adolescents as part of combination antiretroviral therapy (ART), in accordance with WHO and NACO recommendations.
Dosage & Administration
To be administered as per recommended dosing schedules or as prescribed by a healthcare professional.
To be used strictly as part of a combination ART regimen.
Storage
Store below 30°C in a dry place, protected from light and moisture.
Disclaimer
Prescription medicine. To be used only under medical supervision and in line with WHO and NACO treatment guidelines.
Pack Size
60 Tablets